CN113908126A - 一种灵芝孢子油纳米乳及其制备方法 - Google Patents
一种灵芝孢子油纳米乳及其制备方法 Download PDFInfo
- Publication number
- CN113908126A CN113908126A CN202111386420.4A CN202111386420A CN113908126A CN 113908126 A CN113908126 A CN 113908126A CN 202111386420 A CN202111386420 A CN 202111386420A CN 113908126 A CN113908126 A CN 113908126A
- Authority
- CN
- China
- Prior art keywords
- ganoderma lucidum
- spore oil
- lucidum spore
- nanoemulsion
- homogenization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 83
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 83
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000000265 homogenisation Methods 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000003756 stirring Methods 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 239000008367 deionised water Substances 0.000 claims abstract description 10
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 10
- 239000000839 emulsion Substances 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 3
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 64
- 229940109262 curcumin Drugs 0.000 claims description 32
- 235000012754 curcumin Nutrition 0.000 claims description 32
- 239000004148 curcumin Substances 0.000 claims description 32
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 32
- 210000003022 colostrum Anatomy 0.000 claims description 17
- 235000021277 colostrum Nutrition 0.000 claims description 17
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 238000005070 sampling Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 241000222336 Ganoderma Species 0.000 description 24
- 239000000126 substance Substances 0.000 description 6
- 238000001237 Raman spectrum Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000003921 particle size analysis Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Manufacturing & Machinery (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Alternative & Traditional Medicine (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及药物制剂技术领域,具体公开了一种灵芝孢子油纳米乳及其制备方法。所述的灵芝孢子油纳米乳的制备方法,其包含如下步骤:S11.取表面活性剂和有机溶剂混合,搅拌均匀后得溶液;S12.将灵芝孢子油(GLSO)加入到步骤S11制备得到的溶液中,搅拌均匀后加入去离子水,继续搅拌均匀得灵芝孢子油初乳混合物;S13.将灵芝孢子油初乳混合物转移至高压均质机中进行均质得灵芝孢子油纳米乳。由该方法制备得到的灵芝孢子油纳米乳粒径均匀,无论是在水环境还是生理环境下,都能够在6天内保持相对稳定,使得芝孢子油纳米乳的粒径保持在70‑100nm之间。
Description
技术领域
本发明涉及药物制剂技术领域,具体涉及一种灵芝孢子油纳米乳及其制备方法。
背景技术
灵芝孢子油为黄色透明液体,主要成份是灵芝酸、不饱和脂肪酸、灵芝多糖等;其具有护肝、解毒、杀灭癌细胞和止痛等药理作用。但是灵芝孢子油溶解性以及渗透性差。
纳米乳(nanoemulsion)又称微乳液(microemulsion),是由水、油、表面活性剂和助表面活性剂等自发形成,粒径为1~100nm的热力学稳定、各向同性,透明或半透明的均相分散体系;其为难溶性药物相关的研究提供了新思路。已有大量文献报道,纳米药物递送系统可有效改善难溶性药物的溶解度和渗透性,能提高药物生物利用度,增强药物治疗效果并减少对机体的代谢负担。但是现有技术针对灵芝孢子油纳米乳的研究报道较少。发明人在研究中发现,如何制备得到粒径均匀、体系稳定以及不会使得灵芝孢子油的化学结构基团发生改变的灵芝孢子油纳米乳是本发明的难点。
发明内容
为了克服现有技术中存在的至少之一的技术问题,本发明提供了一种灵芝孢子油纳米乳的制备方法。
本发明所要解决的上述技术问题,通过以下技术方案予以实现:
一种灵芝孢子油纳米乳的制备方法,其包含如下步骤:
S11.取表面活性剂和有机溶剂混合,搅拌均匀后得溶液;
S12.将灵芝孢子油(GLSO)加入到步骤S11制备得到的溶液中,搅拌均匀后加入去离子水,继续搅拌均匀得灵芝孢子油初乳混合物;
S13.将灵芝孢子油初乳混合物转移至高压均质机中进行均质得灵芝孢子油纳米乳。
本发明提供了一种全新方法制备得到的灵芝孢子油纳米乳;通过在本发明的上述方法下制备得到的该灵芝孢子油纳米乳粒径均匀。
优选地,步骤S11中的表面活性剂为吐温80。
发明人在大量的研究中惊奇的发现:当表面活性剂选择为吐温80时,其包裹灵芝孢子油提高其稳定性与水溶性的同时,仍能保证其中活性成分的化学结构基团不被改变。
优选地,步骤S11中的有机溶剂为无水乙醇。
优选地,步骤S11中表面活性剂和有机溶剂的体积比为2~4:0.1~0.2;
最优选地,步骤S11中表面活性剂和有机溶剂的体积比为3:0.15。
优选地,步骤S12中,灵芝孢子油(GLSO)与步骤S11制备得到的溶液的体积比为4~6:3~3。
最优选地,步骤S12中,灵芝孢子油(GLSO)与步骤S11制备得到的溶液的体积比为5:3~3.5。
优选地,去离子水与步骤S11制备得到的溶液的体积比为40~45:5~10。
最优选地,去离子水与步骤S11制备得到的溶液的体积比为40~42:8~8.5。
发明人经大量的实验表明,在上述条件参数下制备得到的灵芝孢子油,其粒径均匀,保持在70nm左右。
优选地,在步骤S13中的灵芝孢子油初乳混合物中加入姜黄素,形成灵芝孢子油和姜黄素初乳混合物。
在灵芝孢子油初乳混合物中加入姜黄素,形成灵芝孢子油和姜黄素初乳混合物;二者相互作用,使得灵芝孢子油初乳混合物一方面复合了姜黄素的功效,同时,姜黄素的加入也不会引起灵芝孢子油的化学结构基团的改变;另一方面,发明人惊奇的发现:在灵芝孢子油初乳混合物中加入姜黄素可以进一步大幅提高制备得到的芝孢子油纳米乳的稳定性,使得制备得到的芝孢子油纳米乳无论是在水环境还是生理环境下,都能够在6天内保持相对稳定,使得芝孢子油纳米乳的粒径保持在70-100nm之间。
优选地,姜黄素在灵芝孢子油和姜黄素初乳混合物中的含量为0.1~1.0mg/mL。
最优选地,姜黄素在灵芝孢子油和姜黄素初乳混合物中的含量为0.2~0.8mg/mL。
优选地,步骤S13中的均质包括初步均质和高压均质;
所述初步均质的条件为:均质压力为150~300bar,均质时间为1~3min,出样频率为30~50Hz;所述高压均质的条件为:均质压力为1000~1500bar,均质时间为8~15min,出样频率为30~50Hz。
最优选地,所述初步均质的条件为:均质压力为200bar,均质时间为2min,出样频率为40Hz;所述高压均质的条件为:均质压力为1200bar,均质时间为10min,出样频率为40Hz。
本发明还提供了一种由上述方法制备得到的灵芝孢子油纳米乳。
有益效果:本发明提供了一种全新的灵芝孢子油纳米乳的制备方法,由该方法制备得到的灵芝孢子油纳米乳粒径均匀,体系稳定;此外,本发明还通过加入姜黄素,使得制备得到的灵芝孢子油纳米乳还复合有姜黄素的功效;尤其是,加入姜黄素后是得制备得到的芝孢子油纳米乳无论是在水环境还是生理环境下,都能够在6天内保持相对稳定,使得芝孢子油纳米乳的粒径保持在70-100nm之间。
附图说明
图1为本发明灵芝孢子油纳米乳的粒度分析结果图。
图2为本发明灵芝孢子油纳米乳的TEM(透射电镜)形貌尺寸图。
图3为本发明灵芝孢子油纳米乳的拉曼光谱图。
图4为本发明灵芝孢子油纳米乳的原子力显微镜(AFM)分析图。
图5为本发明灵芝孢子油纳米乳在水环境以及生理环境下的稳定性分析结果图。
具体实施方式
以下结合具体实施例对本发明做进一步详细的说明,但实施例对本发明不做任何形式的限定。
实施例1灵芝孢子油纳米乳的制备
S11.取3mL吐温80(Tween 80)和0.15mL无水乙醇,置于烧杯中,于室温下搅拌5分钟得溶液;
S12.将5mL灵芝孢子油(GLSO)缓慢注入步骤S11制备得到的溶液中,于室温下搅拌5min,继续向其中注入去离子水至终体积为50mL,形成灵芝孢子油初乳混合物;
S13.向步骤S12制备得到的灵芝孢子油初乳混合物中加入10mg姜黄素(CUR),继续搅拌15min,形成灵芝孢子油和姜黄素的初乳混合物,之后转移至高压均质机中进行初步均质和高压均质即得所述的灵芝孢子油纳米乳(简写成GLSO@CUR-0.2mg/mL);
所述的初步均质条件为:均质压力为200bar,均质时间为2min,出样频率为40Hz;所述的高压均质条件为:均质压力为1200bar,均质时间为10min,出样频率为40Hz。
实施例2灵芝孢子油纳米乳的制备
S11.取2mL吐温80(Tween 80)和0.1mL无水乙醇,置于烧杯中,于室温下搅拌5分钟得溶液;
S12.将4mL灵芝孢子油(GLSO)缓慢注入步骤S11制备得到的溶液中,于室温下搅拌5min,继续向其中注入去离子水至终体积为50mL,形成灵芝孢子油初乳混合物;
S13.向步骤S12制备得到的灵芝孢子油初乳混合物中加入20mg姜黄素(CUR),继续搅拌15min,形成灵芝孢子油和姜黄素的初乳混合物,之后转移至高压均质机中进行初步均质和高压均质即得所述的灵芝孢子油纳米乳(简写成GLSO@CUR-0.4mg/mL);
所述的初步均质条件为:均质压力为150bar,均质时间为3min,出样频率为30Hz;所述的高压均质条件为:均质压力为1000bar,均质时间为15min,出样频率为30Hz。
实施例3灵芝孢子油纳米乳的制备
S11.取4mL吐温80(Tween 80)和0.2mL无水乙醇,置于烧杯中,于室温下搅拌5分钟得溶液;
S12.将5mL灵芝孢子油(GLSO)缓慢注入步骤S11制备得到的溶液中,于室温下搅拌5min,继续向其中注入去离子水至终体积为50mL,形成灵芝孢子油初乳混合物;
S13.向步骤S12制备得到的灵芝孢子油初乳混合物中加入40mg姜黄素(CUR),继续搅拌15min,形成灵芝孢子油和姜黄素的初乳混合物,之后转移至高压均质机中进行初步均质和高压均质即得所述的灵芝孢子油纳米乳(简写成GLSO@CUR-0.8mg/mL);
所述的初步均质条件为:均质压力为300bar,均质时间为1min,出样频率为50Hz;所述的高压均质条件为:均质压力为1500bar,均质时间为8min,出样频率为50Hz。
将实施例1~3制备得到的灵芝孢子油纳米乳进行表征实验,实验结果如下:
(1)通过粒度分析检测,我们发现实施例1~3制备得到的灵芝孢子油纳米乳均为70nm左右的球形纳米粒子(图1),随着姜黄素浓度的升高,该纳米体系粒度并未发生明显变化。图(2)TEM结果进一步证明这个结论。同时,灵芝孢子油纳米乳在负染条件下,无磷钨酸吸附,衬度不变,呈现“白色”灵芝孢子油纳米乳。
(2)从图(3)中拉曼光谱结果可知,灵芝孢子油纳米乳在940.3,1306.8,1442.9cm-1的波段具有特征吸收峰,可归属于灵芝孢子油的特征拉曼图谱;此外,在1594.8和1631.5cm-1的波段具有特征吸收峰,可归属于姜黄素的特征拉曼图谱;实施例1~3制备得到的灵芝孢子油纳米乳中属于GLSO的特征吸收峰位置并未发生明显的偏移,这说明以TW80为聚合物外壳构建的纳米体系并不会破坏GLSO中活性成分的特征化学结构,在以聚合物外壳包裹GLSO提高其稳定性与水溶性的同时,仍能保证其中活性成分的化学结构基团不被改变。此外,姜黄素加入以及浓度的增加也不会引起灵芝孢子油的化学结构基团的改变。
(3)通过原子力显微镜(AFM)进一步对实施例1~3制备得到的灵芝孢子油纳米乳进行表征,如图(4)AFM结果可以看出,实施例1~3制备得到的灵芝孢子油纳米乳的纳米尺寸与透射电子显微镜下的颗粒尺寸基本一致,约70nm左右,其厚度约为2-4nm。
(4)我们还对实施例1制备得到的灵芝孢子油纳米乳在不同条件下的稳定性进行了监测分析,图(5)结果表明:实施例1制备得到的灵芝孢子油纳米乳在水环境(DW,distilled water)下能保持相对稳定,实施例1制备得到的灵芝孢子油纳米乳的粒度在144h的监测期内始终保持在70-100nm之间,变化并不明显。在与人血清(Human Serum)共孵育的条件下,实施例1制备得到的灵芝孢子油纳米乳的粒度变化相对明显,即从第144h开始至360h,该纳米体系的粒度由100nm升高至170nm左右。由此可见,无论是在水环境还是生理环境下,本发明制备得到的灵芝孢子油纳米乳都能够在6天内保持相对稳定。
Claims (10)
1.一种灵芝孢子油纳米乳的制备方法,其特征在于,包含如下步骤:
S11.取表面活性剂和有机溶剂混合,搅拌均匀后得溶液;
S12.将灵芝孢子油(GLSO)加入到步骤S11制备得到的溶液中,搅拌均匀后加入去离子水,继续搅拌均匀得灵芝孢子油初乳混合物;
S13.将灵芝孢子油初乳混合物转移至高压均质机中进行均质得灵芝孢子油纳米乳。
2.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,步骤S11中的表面活性剂为吐温80。
3.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,步骤S11中的有机溶剂为无水乙醇。
4.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,步骤S11中表面活性剂和有机溶剂的体积比为2~4:0.1~0.2;
最优选地,步骤S11中表面活性剂和有机溶剂的体积比为3:0.15。
5.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,步骤S12中,灵芝孢子油(GLSO)与步骤S11制备得到的溶液的体积比为4~6:3~3;
最优选地,步骤S12中,灵芝孢子油(GLSO)与步骤S11制备得到的溶液的体积比为5:3~3.5。
6.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,去离子水与步骤S11制备得到的溶液的体积比为40~45:5~10;
最优选地,去离子水与步骤S11制备得到的溶液的体积比为40~42:8~8.5。
7.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,在步骤S13中的灵芝孢子油初乳混合物中加入姜黄素,形成灵芝孢子油和姜黄素初乳混合物。
8.根据权利要求7所述的灵芝孢子油纳米乳的制备方法,其特征在于,姜黄素在灵芝孢子油和姜黄素初乳混合物中的含量为0.1~1.0mg/mL;
最优选地,姜黄素在灵芝孢子油和姜黄素初乳混合物中的含量为0.2~0.8mg/mL。
9.根据权利要求1所述的灵芝孢子油纳米乳的制备方法,其特征在于,步骤S13中的均质包括初步均质和高压均质;
所述初步均质的条件为:均质压力为150~300bar,均质时间为1~3min,出样频率为30~50Hz;所述高压均质的条件为:均质压力为1000~1500bar,均质时间为8~15min,出样频率为30~50Hz;
最优选地,所述初步均质的条件为:均质压力为200bar,均质时间为2min,出样频率为40Hz;所述高压均质的条件为:均质压力为1200bar,均质时间为10min,出样频率为40Hz。
10.权利要求1~9任一项所述的制备方法制备得到的灵芝孢子油纳米乳。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111386420.4A CN113908126A (zh) | 2021-11-22 | 2021-11-22 | 一种灵芝孢子油纳米乳及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111386420.4A CN113908126A (zh) | 2021-11-22 | 2021-11-22 | 一种灵芝孢子油纳米乳及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113908126A true CN113908126A (zh) | 2022-01-11 |
Family
ID=79247807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111386420.4A Pending CN113908126A (zh) | 2021-11-22 | 2021-11-22 | 一种灵芝孢子油纳米乳及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113908126A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110059124A1 (en) * | 2008-02-26 | 2011-03-10 | Guangzhou Hanfang Natural Medicine Research & Development Co.Ltd | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion |
CN103110889A (zh) * | 2013-02-01 | 2013-05-22 | 北京东方红航天生物技术股份有限公司 | 一种有助于增强免疫力的中药及其制备方法 |
CN108785252A (zh) * | 2017-04-27 | 2018-11-13 | 赵玉林 | 一种姜黄素纳米乳及其制备方法 |
CN109876023A (zh) * | 2019-03-08 | 2019-06-14 | 暨南大学 | 一种灵芝孢子油纳米乳及其制备方法与应用 |
-
2021
- 2021-11-22 CN CN202111386420.4A patent/CN113908126A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110059124A1 (en) * | 2008-02-26 | 2011-03-10 | Guangzhou Hanfang Natural Medicine Research & Development Co.Ltd | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion |
CN103110889A (zh) * | 2013-02-01 | 2013-05-22 | 北京东方红航天生物技术股份有限公司 | 一种有助于增强免疫力的中药及其制备方法 |
CN108785252A (zh) * | 2017-04-27 | 2018-11-13 | 赵玉林 | 一种姜黄素纳米乳及其制备方法 |
CN109876023A (zh) * | 2019-03-08 | 2019-06-14 | 暨南大学 | 一种灵芝孢子油纳米乳及其制备方法与应用 |
Non-Patent Citations (3)
Title |
---|
CHENGLIDAI 等: "High-pressure homogenization and tailoring of size-tunable Ganoderma lucidum spore oil nanosystem for enhanced anticancer therapy", 《CHEMICAL ENGINEERING JOURNAL》 * |
RUBIYA KHURSHEED 等: "Exploring role of probiotics and Ganoderma lucidum extract powder as solid carriers to solidify liquid self-nanoemulsifying delivery systems loaded with curcumin", 《CARBOHYDRATE POLYMERS》 * |
梁衍锋等: "姜黄素和灵芝孢子对非酒精性脂肪性肝病ApoB100 mRNA的影响", 《黑龙江医药科学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hussein et al. | Synthesis of carvacrol-based nanoemulsion for treating neurodegenerative disorders in experimental diabetes | |
US20090232855A1 (en) | Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same | |
Güng | New formulation strategies in topical antifungal therapy | |
DE10036871A1 (de) | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe | |
CA2762918A1 (en) | Preparation method of drug loaded emulsion | |
WO2005060935A1 (ja) | 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤 | |
Hiranphinyophat et al. | Particle-stabilized oil-in-water emulsions as a platform for topical lipophilic drug delivery | |
Liu et al. | Enhanced skin permeation of glabridin using eutectic mixture-based nanoemulsion | |
DE10226990A1 (de) | Topisch applizierbare Mikro-Emulsionen mit binärer Phasen- und Wirkstoffdifferenzierbarkeit, deren Herstellung und deren Verwendung, insbesondere zur Versorgung der Haut mit bioverfügbarem Sauerstoff | |
JP2015526483A (ja) | ポリマーフィナステリドナノ粒子、これを含有する水性組成物、脱毛症を治療するための組成物、前記組成物を調製するための方法、およびその使用 | |
Hassan et al. | Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide | |
WO2008043973A1 (fr) | Composition dermatologique comprenant des nanocapsules d' avermectine, son procédé de préparation et son utilisation | |
Ochoa et al. | Preparation and characterization of curcumin nanoemulsions obtained by thin-film hydration emulsification and ultrasonication methods | |
Yasir Siddique et al. | Microemulsified gel formulations for topical delivery of clotrimazole: structural and in vitro evaluation | |
CA2683940A1 (en) | Nanoparticle-coated capsule formulation for dermal drug delivery | |
Morteza-Semnani et al. | Green formulation, characterization, antifungal and biological safety evaluation of terbinafine HCl niosomes and niosomal gels manufactured by eco-friendly green method | |
CN113908126A (zh) | 一种灵芝孢子油纳米乳及其制备方法 | |
WO2006103091A1 (en) | Enhanced delivery of skin benefit agents | |
EP1672025B1 (en) | Finely particulate composite containing carbon compound encapsulated therein | |
CN112263542B (zh) | 地奈德纳米乳凝胶组合物及其制备方法 | |
JP5753089B2 (ja) | 過酸化ベンゾイルの安定分散液を得る方法 | |
Abou Taleb et al. | Promising synthesized bis (arylmethylidene) acetone-polymeric PCL emulsified nanoparticles with enhanced antimicrobial/antioxidant efficacy: in-vitro and in-vivo evaluation | |
KR20120114730A (ko) | 마이크로에멀젼에 의한 감마오리자놀을 함유한 경피약물전달 조성물 | |
Yao et al. | Size-dependence of the skin penetration of andrographolide nanosuspensions: In vitro release-ex vivo permeation correlation and visualization of the delivery pathway | |
CN109260149A (zh) | 一种含有γ-生育三烯酚的纳米乳液及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220111 |